PrismRA is a simple blood test that predicts response to anti-TNF therapies for patients with Rheumatoid Arthritis, so they are prescribed treatments that are more likely to work for them. This test was developed to address and potentially diminish the high costs of taking ineffective drugs on the patient and the healthcare industry. If PrismRA was ordered before prescribing 100% of all anti-TNF drugs in the United States, it would double drug response rates for RA patients from 35% up to 67% while potentially saving over $4.7 billion in wasted prescription costs.
PrismUC is a simple blood test that identifies Ulcerative Colitis patients who do not respond to anti-TNF therapies, so they are prescribed therapies that will more likely work for them. Through the data generated by PrismUC, we will be able to better understand the disease biology and potentially identify new treatment options for these patients who do not respond to drugs on the market today. By bringing precision medicine to patients suffering from UC, $1.3 billion could be saved in ineffective prescriptions.
We have built and deciphered the world’s largest network of highly accurate protein-protein interactions that allows us to interpret individual patient’s gene expression data to uncover disease biology and predict response to specific targets. From these diagnostics tests, our database is continually growing to better understand diseases, potentially uncovering new disease subtypes and identifying new targeted therapies that can be developed to help treat patients more effectively than before.
Anti-TNFs are one of the largest selling drugs in the world, yet less than one-third of patients who are prescribed these drugs respond to them. In fact, 90% of RA patients are given anti-TNFs as a first line treatment despite the low response rate and incredibly high price tag. Patients put their lives on hold while their disease worsens and medical insurance companies and Medicare waste $9 billion each year in prescription costs and related expenses. Scipher saw this clear need and built the tests needed to confront this problem.
Scipher’s platform was the product of a 10-year collaboration between Joseph Loscalzo MD, PhD, Chief of Medicine at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School, and Albert-Laszlo Barabasi, PhD, Director of Northeastern University’s Center for Complex Network Research to build and interpret the first map that describes human disease biology. Brick by brick, they have assembled and interpreted the network of biological processes in human cells, using the most complete classification of protein to protein interactions and algorithms based on network science. Now, we’re able to decipher the biology of each patient’s disease and predict their response to specific treatments using his or her own RNA data.
By collecting RNA expression data from patients through PrismRA and PrismUC, Scipher can identify similarities in the biology of patients who do not respond to current therapies in the market to find new targets that haven’t been considered for RA or UC treatments. These targets can be validated on our platform to guide more effective drug development.
While DNA is the static “blueprint” for all genetic information in every living organism, RNA converts this information to build proteins, the essential building blocks of all cells. RNA and proteins are dynamic and can change over time. When proteins are not produced and controlled correctly in our cells, diseases develop. Understanding how these proteins interact with each other gives us a stronger understanding of a disease’s biology. By combining RNA expression data with this map of protein interactions, we’ve been able to create our revolutionary new platform.